Schlechtweg K, Chen L, St. Clair CM, et al. - Researchers used the National Cancer Database and compared women with neuroendocrine carcinoma of the endometrium (NECE; a rare malignancy) (n = 364) with patients with poorly differentiated endometrioid endometrial cancer (EC) (n = 28,291) in terms of the natural history and outcomes. The likelihood of receiving adjuvant chemotherapy was more in women with NECE, but these patients had less chance of receiving radiation. For NECE and for EC, the median survival was 17 months and 144 months, respectively, and 5-year survival was 38.3% and 68.8%, respectively. The hazard ratio for mortality, in a multivariable model, for women with NECE vs EC was 2.32 (95% CI, 1.88–2.88). NECE was recognized as a rare and aggressive uterine carcinoma. Presentation with later stage disease and having reduced survival was seen in patients with NECE vs those with poorly differentiated EC.